Abstract
Cancer is a set of diseases characterized by unmanageable growth and swelling of abnormal cells. It is the second leading cause of mortality worldwide. Around the world, more than ten million of people are diagnosed with cancer every year and nearly half of the patients ultimately die from it. There are various ways such as chemotherapy, radiation therapy, surgery, bone marrow transplant, immunotherapy, targeted drug therapy, etc. by which cancer can be treated. Various chemical substances are used as drugs to treat cancer, e.g., melphalan, cyclophosphamide, doxorubicin, epirubicin, etoposide, cis-platin, carboplatin, topocan, irinotecan, etc. In most of the cases, the usual cancer drugs are losing their therapeutic values because of poor solubility, lack of tumor selectivity, and multidrug resistance property of cancer cells. In this scenario, expansion of therapeutic modality is urgently needed. Nowadays, peptide-based drugs are promisingly used to treat many diseases including cancer. To treat cancer, peptides are used in various ways such as drug, vaccine, drug carrier, hormone, radionuclide carrier, etc. In this chapter, we have taken an attempt to provide an overview of applications of peptide drugs in diagnosis and treatment of various types of cancers.
This is a preview of subscription content, log in via an institution to check access.
References
Baskar R, Lee KA, Yeo R, Yeoh K-W (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9(3):193–199. https://doi.org/10.7150/ijms.3635
Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, Koppelhus U (2006) Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 17(3):750–758. https://doi.org/10.1021/bc050283q
Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C (2008) Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 123(6):1227–1239. https://doi.org/10.1002/ijc.23754
Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19(22):3794–3804. https://doi.org/10.2174/092986712801661004
Brezden A, Mohamed MF, Nepal M, Harwood JS, Kuriakose J, Seleem MN, Chmielewski J (2016) Dual targeting of intracellular pathogenic bacteria with a cleavable conjugate of kanamycin and an antibacterial cell-penetrating peptide. J Am Chem Soc 138(34):10945–10949. https://doi.org/10.1021/jacs.6b04831
Broqua P, Riviere PJM, Conn PM, Rivier JE, Aubert ML, Junien J-L (2002) Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: Degarelix. J Pharmacol Exp Ther 301(1):95. https://doi.org/10.1124/jpet.301.1.95
Chatal JF, Hoefnagel CA (1999) Radionuclide therapy. Lancet 354(9182):931–935. https://doi.org/10.1016/s0140-6736(99)06002-x
Chen CH, Lu TK (2020) Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics (Basel) 9(1):24. https://doi.org/10.3390/antibiotics9010024
Chung SW, Lee BS, Choi J, Kim SW, Kim I-S, Kim SY, Byun Y (2015) Optimization of a stable linker involved DEVD peptide-doxorubicin conjugate that is activated upon radiation-induced Caspase-3-mediated apoptosis. J Med Chem 58(16):6435–6447. https://doi.org/10.1021/acs.jmedchem.5b00420
Clare A, Kay AB, Mark L (2002) Peptide-based vaccines in the treatment of specific allergy. Curr Drug Targets Inflamm Allergy 1(4):353–361. https://doi.org/10.2174/1568010023344562
Dash A, Chakraborty S, Pillai MRA, Knapp FF (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 30(2):47–71. https://doi.org/10.1089/cbr.2014.1741
Debruyne F, Bhat G, Garnick MB (2006) Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2(6):677–696. https://doi.org/10.2217/14796694.2.6.677
Derakhshankhah H, Jafari S (2018) Cell penetrating peptides: a concise review with emphasis on biomedical applications. Biomed Pharmacother 108:1090–1096. https://doi.org/10.1016/j.biopha.2018.09.097
Drin G, Cottin S, Blanc E, Rees AR, Temsamani J (2003) Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278(33):31192–31201. https://doi.org/10.1074/jbc.M303938200
Elisabeth G, Didier B, Pascal D (2007) Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 7(5):552–558. https://doi.org/10.2174/187152007781668706
Emons G, Tomov S, Harter P, Sehouli J, Wimberger P, Staehle A, Hanker LC, Hilpert F, Dall P, Gruendker C (2010) Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol 28(15_suppl):5035–5035. https://doi.org/10.1200/jco.2010.28.15_suppl.5035
Faintuch B, Pereira NS, Faintuch S, Muramoto E, Silva C (2003) Direct labeling studies of octapeptides with rhenium-188. Radiochimica Acta 91:427–432. https://doi.org/10.1524/ract.91.7.427.20013
Falzone L, Salomone S, Libra M (2018) Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9:1300–1300. https://doi.org/10.3389/fphar.2018.01300
Gaspar D, Veiga AS, Castanho MARB (2013) From antimicrobial to anticancer peptides. A Rev Frontier Microbiol 4:294. https://doi.org/10.3389/fmicb.2013.00294
Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55(6):1179–1188. https://doi.org/10.1016/0092-8674(88)90262-0
Hruby VJ, Matsunaga TO (2002) In: Grant GA (ed) Synthetic peptides, 2nd edn. Oxford University Press, New York, pp 292–376
Joensuu H, Tenhunen M (1999) Physical and biological targeting of radiotherapy. Acta oncologica (Stockholm, Sweden) 38(Suppl 13):75–83. https://doi.org/10.1080/028418699432806
Johansson HJ, El-Andaloussi S, Holm T, Mäe M, Jänes J, Maimets T, Langel Ü (2008) Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol Ther 16(1):115–123. https://doi.org/10.1038/sj.mt.6300346
Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 88(5):1864–1868. https://doi.org/10.1073/pnas.88.5.1864
Lee JY, Suh JS, Kim JM, Kim JH, Park HJ, Park YJ, Chung CP (2015) Identification of a cell-penetrating peptide domain from human beta-defensin 3 and characterization of its anti-inflammatory activity. Int J Nanomedicine 10:5423–5434. https://doi.org/10.2147/ijn.S90014
Lei J, Sun L, Huang S, Zhu C, Li P, He J, Mackey V, Coy DH, He Q (2019) The antimicrobial peptides and their potential clinical applications. Am J Transl Res 11(7):3919–3931
Li L, Shi Y, Cheng X, Xia S, Cheserek MJ, Le G (2015) A cell-penetrating peptide analogue, P7, exerts antimicrobial activity against Escherichia coli ATCC25922 via penetrating cell membrane and targeting intracellular DNA. Food Chem 166:231–239. https://doi.org/10.1016/j.foodchem.2014.05.113
Lien S, Lowman HB (2003) Therapeutic peptides. Trends Biotechnol 21(12):556–562. https://doi.org/10.1016/j.tibtech.2003.10.005
Ma X, Yu H (2006) Global burden of cancer. Yale J Biol Med 79(3-4):85–94
Magzoub M, Staffan S, Pontus L, Oglecka K, Lilja J, Wittrup A, Eriksson LEG, Langel Ü, Belting M, Astrid G (2006) N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun - BBRC 348(2):379–385. https://doi.org/10.1016/j.bbrc.2006.07.065
Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD (2002) Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 277(33):30208–30218. https://doi.org/10.1074/jbc.m204202200
Marqus S, Pirogova E, Piva TJ (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24(1):21. https://doi.org/10.1186/s12929-017-0328-x
McGregor DP (2008) Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 8(5):616–619. https://doi.org/10.1016/j.coph.2008.06.002
Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 15(8):829–840. https://doi.org/10.1016/s1470-2045(14)70236-0
Migliorini D, Dutoit V, Allard M, GrandjeanHallez N, Marinari E, Widmer V, Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N, Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D, Vargas M-I, Walker PR, Patrikidou A, Dietrich P-Y (2019) Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol 21(7):923–933. https://doi.org/10.1093/neuonc/noz040
Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, MartÃn C, Ragulin Y, Zukin M, Helwig C, Falk M, Butts C, Shepherd FA (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 26(6):1134–1142. https://doi.org/10.1093/annonc/mdv104
Nan YH, Park I-S, Hahm K-S, Shin SY (2011) Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs. J Pept Sci 17(12):812–817. https://doi.org/10.1002/psc.1408
Oh EJ, Choi J-S, Kim H, Joo C-K, Hahn SK (2011) Anti-Flt1 peptide e hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials 32:3115e3123. https://doi.org/10.1016/j.biomaterials.2011.01.003
Okarvi SM (2004) Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 24(3):357–397. https://doi.org/10.1002/med.20002
Park K, Kim Y-S, Lee GY, Park R-W, Kim I-S, Kim SY, Byun Y (2008) Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 25(12):2786. https://doi.org/10.1007/s11095-008-9643-y
Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E (2002) A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A 99(11):7444–7449. https://doi.org/10.1073/pnas.062189599
Pujals S, Giralt E (2008) Proline-rich, amphipathic cell-penetrating peptides. Adv Drug Deliv Rev 60(4):473–484. https://doi.org/10.1016/j.addr.2007.09.012.1
Ragin AD, Morgan RA, Chmielewski J (2002) Cellular import mediated by nuclear localization signal peptide sequences. Chem Biol 9(8):943–948. https://doi.org/10.1016/s1074-5521(02)00189-8
Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JWA (2016) A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res 22(19):4776–4785. https://doi.org/10.1158/1078-0432.CCR-16-0506
Regberg J, Srimanee A, Langel U (2012) Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel) 5(9):991–1007. https://doi.org/10.3390/ph5090991
Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B (2003) Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278(1):585–590. https://doi.org/10.1074/jbc.M209548200
Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T (2016) IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17(11):1599–1611. https://doi.org/10.1016/S1470-2045(16)30408-9
Schally AV, Nagy A (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141(1):1–14. https://doi.org/10.1530/eje.0.1410001
Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z (2000) Peptide analogs in the therapy of prostate cancer. Prostate 45(2):158–166. https://doi.org/10.1002/1097-0045(20001001)45:2<158::AID-PROS10>3.0.CO;2-K
Smolarczyk R, Cichoń T, Graja K, Hucz J, Sochanik A, Szala S (2006) Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta BiochimicaPolinica 53(4):801–805
Song J, Zhang Y, Zhang W, Chen J, Yang X, Ma P, Zhang B, Liu B, Ni J, Wang R (2015) Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin. Peptides 63:143–149. https://doi.org/10.1016/j.peptides.2014.12.00
Srimanee A, Arvanitidou M, Kim K, Hällbrink M, Langel Ü (2018) Cell-penetrating peptides for siRNA delivery to glioblastomas. Peptides 104:62–69. https://doi.org/10.1016/j.peptides.2018.04.015
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich P-Y, Pietsch T, Hicking C, Tonn J-C, Diserens A-C, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of Cilengitide and Temozolomide with concomitant radiotherapy followed by Cilengitide and Temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712–2718. https://doi.org/10.1200/JCO.2009.26.6650
Thundimadathil J (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012:967347–967347. https://doi.org/10.1155/2012/967347
Tripathi PP, Arami H, Banga I, Gupta J, Gandhi S (2018) Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy. Oncotarget 9(98):37252–37267. https://doi.org/10.18632/oncotarget.26442
Walrant A, Matheron L, Cribier S, Chaignepain S, Jobin M-L, Sagan S, Alves ID (2013) Direct translocation of cell-penetrating peptides in liposomes: a combined mass spectrometry quantification and fluorescence detection study. Anal Biochem 438(1):1–10. https://doi.org/10.1016/j.ab.2013.03.009
Wan G, Cheng Y, Song J, Chen Q, Chen B, Liu Y, Ji S, Chen H, Wang Y (2020) Nucleus-targeting near-infrared nanoparticles based on TAT peptide-conjugated IR780 for photo-chemotherapy of breast cancer. Chem Eng J 380:122458. https://doi.org/10.1016/j.cej.2019.122458
Wang C, Wang X, Zhong T, Zhao Y, Zhang W-Q, Ren W, Huang D, Zhang S, Guo Y, Yao X, Tang Y-Q, Zhang X, Zhang Q (2015) The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo. Int J Nanomedicine 10:2229–2248. https://doi.org/10.2147/IJN.S79840
Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97(24):13003–13008. https://doi.org/10.1073/pnas.97.24.13003
Yang W, Xia Y, Fang Y, Meng F, Zhang J, Cheng R, Deng C, Zhong Z (2018) Selective cell penetrating peptide-functionalized Polymersomes mediate efficient and targeted delivery of methotrexate disodium to human lung cancer in vivo. Adv Healthc Mater 7(7):1701135. https://doi.org/10.1002/adhm.201701135
Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR (2004) Synthesis and evaluation of Bombesin derivatives on the basis of pan-Bombesin peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for targeting Bombesin receptor-expressing Tumors. Cancer Res 64(18):6707. https://doi.org/10.1158/0008-5472.CAN-03-3845
Zheng L-H, Wang Y-J, Sheng J, Wang F, Zheng Y, Lin X-K, Sun M (2011) Antitumor peptides from marine organisms. Mar Drugs 9(10):1840–1859. https://doi.org/10.3390/md9101840
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Biswas, S., Naskar, J. (2022). Applications of Peptide in Cancer Therapy. In: Chakraborti, S. (eds) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-16-1247-3_39-1
Download citation
DOI: https://doi.org/10.1007/978-981-16-1247-3_39-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-1247-3
Online ISBN: 978-981-16-1247-3
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences